SEC EDGARJUL 82 min read$MCK

TYLER BRIAN S. sold $6.7M of MCK

TYLER BRIAN S. (Chief Executive Officer) sold 8,463 shares of MCKESSON CORP (MCK) at $793.56 ($6.72M total) on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · TYLER BRIAN S.

Published Jul 8, 2026, 8:25 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jul 8, 2026, 8:26 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$MCK

Neutral

medium confidence

Mentioned

$MCK

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$MCKNeutralLow

Why it matters

Traders may monitor insider activity for sentiment, but 10b5-1 plans generally limit the informational content about near-term business performance.

Market read

A CEO open-market sale of about $6.72M in McKesson shares was reported, but it is scheduled under a 10b5-1 plan.

What to watch

The filing does not disclose reasons for the sale, and 10b5-1 schedules can be triggered regardless of current fundamentals or sentiment.

Relevance 5/10Novelty 5/10Timing: SEC Form 4 filed 2026-07-08 for a 2026-07-07 insider sale.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for McKesson (MCK).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MCKNeutralMedium confidence

Context

McKesson CEO Tyler Brian S. filed a Form 4 selling 8,463 shares at $793.56 for about $6.72M under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this filing; any impact is likely short-lived.

Evidence & confidence

The transaction is an open-market sale by the CEO, explicitly under a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

Minimal sector read-through; this is company-specific insider transaction data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A large CEO sale can be interpreted as confidence in liquidity needs or diversification rather than negative outlook, especially with a 10b5-1 plan.

Key entities

issuer
MCKESSON CORP
Company whose CEO insider sale is disclosed on Form 4.
insider
TYLER BRIAN S.
McKesson CEO and director who sold shares.
trading mechanism
Rule 10b5-1 plan
Pre-arranged plan that typically reduces interpretive weight of insider sales.

Read at source ← All news

SEP 15

$MCKMed

Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)?

McKesson (MCK) raised its full-year EPS guidance to 13-15% (15-17% excluding prior-year items) and plans to rebrand its Medical-Surgical unit as Wellverse, targeting an IPO in 2H 2027. The company also aims to acquire Precision Medicine Group to expand oncology and biopharma services. Management highlights core operations are tracking ahead, but structural pressures on drug pricing and high leverage remain risks. McKesson projects $502.2B revenue and $6.3B earnings by 2029, implying 6.9% yearly

simplywall.st3 min

SEP 14

$MCKHigh

McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal

McKesson (MCK) raised its outlook, citing growth in its Oncology & Multispecialty segment, which saw 33% revenue growth and 41% adjusted operating profit growth in Q1. The company also announced a deal for Precision Medicine Group, expected to be strategically and financially accretive. McKesson's RxTS segment grew 9% in revenue and 13% in adjusted operating profit, with GLP-1-related business accounting for 11% of its revenue. The company plans to invest more in growth, automation, and technolo

yahoo.com2 min

SEP 8

$MCKMed

McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

McKesson (MCK) plans a $2.25B precision medicine acquisition, expecting strategic alignment and value creation. Q1 revenue grew 5% in North American Pharmaceutical Distribution and 33% in Oncology. The company aims to return $5B to shareholders this year, including $2.5B in share repurchases and a 15% dividend increase. McKesson also expects to separate its Medical-Surgical business, rebranded as Wellverse, by late 2024.

yahoo.com6 min

SEP 7

$CAHMedAI 8/10

4 companies on verge of settling US opioid lawsuits

AmerisourceBergen, Cardinal Health, McKesson, and Johnson & Johnson are nearing a $26B settlement for opioid lawsuits. New York reached a separate $1B deal with the distributors. Johnson & Johnson will contribute up to $5B nationally. Trials continue elsewhere.

pressdemocrat.com3 min

SEP 6

$MCKMedAI 8/10

McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy

McKesson (NYSE:MCK) to acquire Precision Medicine Group for $2.25B, expanding its oncology and specialty care business. The deal aims to enhance clinical research and commercialization services, with Precision Medicine joining McKesson's Oncology & Multispecialty segment. McKesson has been divesting non-core assets to fund such investments, and the Oncology segment saw 33% revenue growth in Q1 2026. However, the deal's timeline and integration risks remain uncertain.

yahoo.com3 min

SEP 5

$MCKHighAI 8/10

McKesson Stock: Is MCK Outperforming the Healthcare Sector?

McKesson (MCK), a $107.4B healthcare distributor, has outperformed the sector, rising 24.6% in 3 months and 33.4% in 52 weeks. Q1 2027 revenue hit $105.4B, up 7.7% YoY, with adjusted EPS of $9.93. The company raised full-year EPS guidance to $44.60. Analysts rate MCK a 'Strong Buy' with a $984.29 price target.